Microeconomics: Cost Structures, Profit Maximization, and Pharmaceutical Pricing
Fundamentals of Cost Structure and Marginal Analysis
Marginal Cost (): Represents the incremental change in total cost resulting from producing one additional unit of output.
Total Cost () Calculation: Determined across various production levels () by combining fixed and variable components.
Practice Problem Context: Standard applications include evaluated scenarios such as problem Number 7 and Number 17, which showcase concepts across three distinct problem versions.
Research Assignment Guidelines
Assignment Format: An optional research assignment focused on microeconomics topics that allow flexible submission types, including formal written research papers.
Objective: Designed to give opportunity for exploring real-world applications and critical policy implications connected to microeconomic principles.
Components of Total Cost: Fixed vs. Variable
Fixed Cost ():
Defined as the cost incurred when output quantity is zero ().
Remains constant across all levels of production quantity ().
Graphically represented as a flat horizontal component that is identical at every output level.
Variable Cost ():
Costs that change directly in response to changes in output quantity ().
Total Cost Structure:
Profit Maximization Criteria
Profit Evaluation: Calculated for all output and pricing combinations using the relationship:
Optimal Output and Pricing:
Under baseline conditions, profit maximization occurs at an output quantity of and a price of
Maximization Criterion: The profit-maximizing quantity satisfies the condition where Marginal Revenue equals Marginal Cost ().
Impact of Shifts in Fixed Cost:
An increase in fixed costs (e.g., increasing fixed costs to ) shifts the entire Total Cost curve vertically upward by the amount of the increase.
Irrelevance of Fixed Costs in Pricing and Quantity Decisions
Monopoly Price and Production Rule:
When fixed costs change, a profit-maximizing monopolist alters nothing regarding its production quantity or product price.
Fixed costs are completely irrelevant for determining optimal production quantity and selling price on the supply side because Marginal Cost () is determined exclusively by Variable Cost ().
Impact on Overall Profit:
Fixed costs affect the magnitude of total profit ( decreases as increases).
Fixed costs do not shift the profit-maximizing intersection where
Illustrative Scenarios:
Executive Compensation: If a chief executive officer's (CEO) salary increases from to , this raises fixed costs but does not alter the price the firm charges for its product.
Overhead and Taxes: Doubling property taxes for a firm (e.g., GlaxoSmithKline or hypothetical monopolies) lowers net profit but leaves the profit-maximizing price and quantity unchanged.
Case Study: Pharmaceutical Pricing of Compavir (Commavir)
Research and Development Costs:
Prior to market introduction, hundreds of millions of dollars are spent on scientific R&D, development, and regulatory testing.
Once approved and brought to market, these development expenses represent sunk fixed costs and are irrelevant to setting ongoing price and quantity.
GlaxoSmithKline (GSK) Strategy:
GSK priced Compavir (Commavir) at per year / per dose.
The active ingredients cost only about per dose.
GSK established the price point by evaluating where to achieve maximum profit.
Cost Drivers:
High management expenses (million-dollar executive compensation).
Marketing Expenditures: Approximately one-third of every dollar (over out of the price) is spent directly on marketing new drugs.
Market Segmentation, Price Elasticity, and Generic Competition
Demand Elasticity Variation:
Price-insensitive consumer segments display a steep, nearly vertical demand curve, sustaining high prices.
Low-income demographics feature low individual purchasing power, making a price unaffordable for the majority of the population.
Cipla Generic Entry Model:
Cipla conducts economic profit analysis for lower-income consumer bases and sets a price of approximately
Total Revenue Curve Structure:
Exhibits an inverted U-shape.
Because the demand curve is much flatter across a vastly larger volume of customers, Cipla's Total Revenue curve is significantly flattened compared to high-price models.
Cost Structure Comparison:
Fixed Costs: Cipla operates with significantly lower fixed costs than GSK, as it avoids high management salaries and marketing overhead.
Variable Costs: Approximately identical to GSK at roughly per unit for active ingredients, plus minor additional costs for packaging.
Total Cost Curve Mechanics: The slope of Cipla's Total Cost curve (determined by variable costs) matches GSK's, but Cipla's vertical intercept (fixed cost) is substantially lower.
Target Operating Points:
Profit Maximization: Occurs at output where , generating a price of approximately
Breakeven Point: Occurs where Total Revenue equals Total Cost (), resulting in